Home/ Stocks/ ALMS

Alumis Inc. Common Stock

ALMS XNAS

$25.50 +0.19 (+0.75%) ▲ 15-min delayed

Open

$25.05

High

$25.71

Low

$24.90

Volume

844.0K

Market Cap

$3.28B

About Alumis Inc. Common Stock

Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 239 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$1.66M	$-142,221,000	$-1.11
Q1 2026	$1.74M	$-93,053,000	$-0.74
FY 2025	$24.05M	$-243,325,000	$-2.86
Q3 2025	$2.07M	$-110,752,000	$-1.06

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 11, 2026

Calendar →

Related Market News

No specific coverage for ALMS yet. Check out our latest market news or earnings calendar.

Get ALMS Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Alumis Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.